Abbott Laboratories (ABT) Stock Forecast & Price Target

$128.69 +1.06 (+0.83%)

Closing price 10/17/2025 03:59 PM Eastern

Extended Trading

$128.52 -0.16 (-0.13%)

As of 10/17/2025 07:59 PM Eastern

Compare

Abbott Laboratories - Analysts' Recommendations and Stock Price Forecast (2025)

Consensus Rating

Moderate Buy

Based on 22 Analyst Ratings

Sell
0

Hold
4

Buy
18

Based on 22 Wall Street analysts who have issued ratings for Abbott Laboratories in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 22 analysts, 4 have given a hold rating, 16 have given a buy rating, and 2 have given a strong buy rating for ABT.

Consensus Price Target

$147.61
14.70% Upside

According to the 22 analysts' twelve-month price targets for Abbott Laboratories, the average price target is $147.61. The highest price target for ABT is $162.00, while the lowest price target for ABT is $137.00. The average price target represents a forecasted upside of 14.70% from the current price of $128.69.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for ABT and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Abbott Laboratories and its competitors.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ABT Analyst Ratings Over Time

Type	Current Forecast 10/18/24 to 10/18/25	1 Month Ago 9/18/24 to 9/18/25	3 Months Ago 7/20/24 to 7/20/25	1 Year Ago 10/19/23 to 10/18/24
Strong Buy	2 Strong Buy rating(s)	2 Strong Buy rating(s)	2 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	16 Buy rating(s)	16 Buy rating(s)	16 Buy rating(s)	12 Buy rating(s)
Hold	4 Hold rating(s)	4 Hold rating(s)	5 Hold rating(s)	4 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$147.61	$144.47	$144.47	$129.67
Forecasted Upside	14.70% Upside	7.28% Upside	16.69% Upside	8.61% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

ABT Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

ABT Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Abbott Laboratories Stock vs. The Competition

Type	Abbott Laboratories	Medical Companies	S&P 500
Consensus Rating Score	2.91	2.33	2.52
Consensus Rating	Moderate Buy	Hold	Moderate Buy
Predicted Upside	14.70% Upside	1,357.67% Upside	13.61% Upside
News Sentiment Rating	Positive News See Recent ABT News	Neutral News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
10/17/2025	Barclays 3 of 5 stars	Matt Miksic Not Rated	Boost Target	Overweight	$159.00 ➝ $162.00	+27.18%
10/16/2025	Wells Fargo & Company 3 of 5 stars	Lawrence Biegelsen Not Rated	Boost Target	Overweight	$142.00 ➝ $146.00	+12.80%
10/16/2025	Royal Bank Of Canada 3 of 5 stars	Shagun Singh Not Rated	Reiterated Rating	Outperform	$147.00	+13.57%
10/16/2025	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jayson Bedford Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Outperform	$141.00 ➝ $146.00	+12.67%
10/16/2025	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target	Outperform	$145.00 ➝ $150.00	+15.76%
10/16/2025	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Matthew Taylor Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$145.00 ➝ $149.00	+14.99%
10/15/2025	Evercore ISI Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Vijay Kumar Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Outperform	$144.00 ➝ $142.00	+9.58%
10/15/2025	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Marie Thibault Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Buy	$145.00	+12.10%
10/14/2025	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Anthony Petrone Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Neutral	$135.00 ➝ $140.00	+6.06%
10/10/2025	Benchmark Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Bruce Jackson Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Buy	$145.00	+8.83%

10/8/2025	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Buy (B)
10/1/2025	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target	Buy	$153.00 ➝ $157.00	+16.35%
7/17/2025	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Strong-Buy
7/15/2025	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Lewis Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Equal Weight	$127.00 ➝ $137.00	+3.75%
6/16/2025	Leerink Partnrs Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	M. Kratky Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Hold
6/16/2025	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Initiated Coverage	Market Perform	$143.00	+5.61%
4/17/2025	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Adam Maeder Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Overweight	$133.00 ➝ $145.00	+9.98%
4/17/2025	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Rick Wise Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$135.00 ➝ $145.00	+11.76%
3/10/2025	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Travis Steed Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$133.00 ➝ $150.00	+8.03%
3/4/2025	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Joanne Wuensch Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$135.00 ➝ $160.00	+15.20%
1/28/2025	Argus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	D. Toung Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Strong-Buy
1/23/2025	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Danielle Antalffy Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$146.00 ➝ $148.00	+25.68%
10/8/2024	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Initiated Coverage	Outperform	$130.00	+14.69%
9/19/2024	Piper Sandler Companies Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Initiated Coverage	Overweight	$131.00	+14.04%
7/30/2024	Edward Jones Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Buy ➝ Hold

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 08:43 AM ET.

Should I Buy Abbott Laboratories Stock? ABT Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, October 15, 2025. Please send any questions or comments about these Abbott Laboratories pros and cons to contact@marketbeat.com.

Abbott Laboratories
Bull Case

Here are some ways that investors could benefit from investing in Abbott Laboratories:

The current stock price is around $132, which is near its 50-day moving average, indicating stability in recent trading.
Abbott Laboratories reported a strong quarterly revenue of $11.14 billion, exceeding analyst expectations, showcasing robust business performance.
The company has a solid return on equity of 18.32%, reflecting effective management and profitability in generating returns for shareholders.
Abbott Laboratories has a low debt-to-equity ratio of 0.25, suggesting a conservative approach to leveraging, which can be appealing to risk-averse investors.
The recent dividend announcement of $0.59 per share, with a yield of 1.8%, provides a steady income stream for investors, supported by a reasonable payout ratio of 29.57%.

Abbott Laboratories
Bear Case

Investors should be bearish about investing in Abbott Laboratories for these reasons:

The P/E ratio of 16.48 may indicate that the stock is fairly valued, limiting potential upside for growth-oriented investors.
Analysts have mixed ratings, with some suggesting a "neutral" outlook, which may signal uncertainty about future performance.
Despite recent revenue growth, the P/E/G ratio of 2.51 suggests that the stock may be overvalued relative to its earnings growth potential.
Insider transactions, such as the CFO selling shares, could raise concerns about the company's future prospects and insider confidence.
The beta of 0.69 indicates lower volatility compared to the market, which may not appeal to investors seeking high-risk, high-reward opportunities.

ABT Forecast - Frequently Asked Questions

: According to the research reports of 22 Wall Street equities research analysts, the average twelve-month stock price forecast for Abbott Laboratories is $147.61, with a high forecast of $162.00 and a low forecast of $137.00.
: 22 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Abbott Laboratories in the last year. There are currently 4 hold ratings, 16 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ABT shares.
: According to analysts, Abbott Laboratories's stock has a predicted upside of 14.70% based on their 12-month stock forecasts.
: Abbott Laboratories has been rated by research analysts at Barclays, Benchmark, BTIG Research, Evercore ISI, Jefferies Financial Group, Mizuho, Raymond James Financial, Royal Bank Of Canada, Sanford C. Bernstein, The Goldman Sachs Group, Weiss Ratings, and Wells Fargo & Company in the past 90 days.
: Analysts like Abbott Laboratories more than other "medical" companies. The consensus rating for Abbott Laboratories is Moderate Buy while the average consensus rating for "medical" companies is Hold. Learn more on how ABT compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top-Rated Stocks

More Ratings Tools

This page (NYSE:ABT) was last updated on 10/18/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Abbott Laboratories (ABT) Stock Forecast & Price Target